Bioethicists of life extension stories

Jun 23, 2026

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.

Jun 23, 20262 sources

Bioethicists of life extension stories

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

FDA Pushes Drugmakers to Report Missing Clinical Trial Results

FDA Rejects Replimune's Skin Cancer Drug for Second Time

Merck's Experimental HIV Prevention Pill Could Be Manufactured for Under $5 Annually, Researchers Say

FDA Approves Eli Lilly's Obesity Pill, Setting Up Competition with Novo Nordisk

Doctors Without Borders Accuses Gilead of Refusing to Sell HIV Prevention Drug Lenacapavir

Related timelines

Iran War

US Congress

Venture capital funding

Strait of Hormuz blockage

Trump administration